Synergistic induction of endothelial tissue factor by tumor necrosis factor and vascular endothelial growth factor: functional analysis of the tumor necrosis factor receptors  by Clauss, Matthias et al.
FEBS Letters 390 (1996) 334-338 FEBS 17299 
Synergistic induction of endothelial tissue factor by tumor necrosis factor 
and vascular endothelial growth factor: functional analysis of the tumor 
necrosis factor receptors 
Matthias Clauss a,*, Matthias Grell b, Carmen Fangmann a, Walter Fiers c, Peter Scheurich b, 
Werner Risau a 
aAbteilung fiir Molekulare Zellbiologie, Max-Planek-Institut far Physiologische und Klinische Forschung, 61231 Bad Nauheim, Germany 
blnstitut fiir Zellbiologie und Immunologic, Universitiit Stuttgart, 70569 Stuttgart, Germany 
CLaboratory of Molecular Biology, University of Ghent, K.L. Ledeganckstraat 35, 9000 Ghent, Belgium 
Received 12 June 1996 
Abstract Tissue factor expression on the surface of endothefial 
cells can be induced by tumor necrosis factor (TNF) and vascular 
endothelial growth factor (VEGF) in a synergistic manner. We 
have investigated the role of the two different TNF receptors for 
this synergy. Firstly, stimulation of the 60 kDa TNF receptor 
(TNFR60) by a mutant of TNF specific for TNFR60 induced 
responses comparable to wild-type TNF. In contrast, stimulation 
of TNFR80 by a TNFR80-specific TNF mutein did not result in 
enhancement of tissue factor expression even in the presence of a 
suboptimal TNFR60 triggering. Secondly, we tested neutralizing 
TNF receptor antibodies for inhibition of tissue factor synthesis 
induced by VEGF and TNF. A TNFR60-specific antibody 
inhibited tissue factor production over a broad range of TNF 
concentrations, indicating an essential role of TNFR60 in the 
TNF/VEGF synergy. In contrast, blocking of TNF binding to 
TNFR80 strongly inhibited TNF-induced tissue factor expres- 
sion at low, but less pronounced at high, TNF concentrations. In
conclusion, these data are in agreement with a model in which 
TNFR80 participates in the synergy between VEGF and low 
concentrations of soluble TNF by passing the ligand to the 
signalling TNFR60. 
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1. Introduction 
TNF is a pleiotropic ytokine showing bioactivity on a 
variety of different cell types, a phenomenon which may be 
explained in part by the existence of two functionally distinct 
TNF receptors, designated TNFR60 and TNFR80. By means 
of selective agonistic/antagonistic TNF receptor antibodies [1] 
and mutants of TNF [2,3], specific for either one of the TNF 
receptors, the association of biological activities with the in- 
dividual TNF receptors had been analyzed in vitro and in 
vivo. The cellular effects of TNF in vitro such as cytotoxicity 
towards tumor cells [1], stimulation of fibroblast growth [4], 
tissue factor induction in endothelial cells [5,6] and expression 
of endothelial cell adhesion proteins [7] are reportedly asso- 
ciated with signalling by the TNFR60 receptor. In contrast, 
GM-CSF secretion and thymocyte proliferation emerged to be 
mediated by the TNFR80 receptor [1,8]. In further in vivo 
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studies, a TNF mutant specific for TNFR60 was shown to 
produce toxicity in baboons [9]. Furthermore, the essential 
role of the TNFR60 in TNF-induced host response (leukocyte 
organ infiltration) and lethal septic shock was confirmed by 
studies employing mouse mutants deficient in the TNFR60 
[10-12], but TNFR80-deficient mice also appeared to be less 
sensitive to TNF-mediated lethality [13]. It has been proposed 
that the TNFR80 may participate in TNFR60 action by rais- 
ing the actual concentration of TNF in proximity of the 
TNFR60. This ligand passing mechanism [14] should be 
most pronounced at low concentrations of TNF due to the 
lower Kd of the TNFR60 compared to the TNFR80. 
Although TNF was discovered and isolated by its ability to 
induce hemorrhagic necrosis in transplantable methylcholan- 
threne (meth A)-induced fibrosarcomas of mice, the mechan- 
ism underlying this induction of tumor necrosis had not been 
intensively studied. The ability of TNF to exert toxic effects 
against a number of tumor cell lines in vitro was quoted in 
favor of a direct anti-tumor effect in vivo. As late as 20 years 
after the discovery of TNF as a tumor necrosis inducing fac- 
tor, involvement of the tumor vasculature became obvious. 
Starting from studies showing that TNF does not affect un- 
vascularized and intraperitoneally growing meth A sarcomas, 
intravasal fibrin deposition after systemic TNF treatment and 
inhibition of the antitumoral effect of TNF by anticoagulants 
were demonstrated [15,16]. In order to explain the exclusive 
tumor localization of these events, it was proposed that se- 
creted tumor factors could enhance the TNF-mediated induc- 
tion of endothelial tissue factor [15,17-19]. One of these cyto- 
kines, the vascular endothelial growth factor/vascular 
permeability factor (VEGF) can induce tissue factor produc- 
tion on cultured human endothelial cells. This production is 
supported synergistically b  TNF concentrations a  low as 5 
pM [18]. As tissue factor is considered the major initiator of 
coagulation i  vivo [20], this synergistic VEGF-TNF interac- 
tion may be an important mechanism in TNF-induced tumor 
necrosis [21]. 
Induction of tumor necrosis by systemic administration f
TNF in mice is much more efficient with murine TNF than 
with human TNF [22]. Since human TNF does not bind to 
murine TNFR80 but to murine TNFR60, TNFR80 appears 
to be involved in the tumor necrosis induction by TNF. In 
addition, TNFR80 has also been shown to be essential for 
another TNF-induced necrosis, namely skin necrosis [23]. 
Therefore, it seems to be reasonable to expect that any in 
vitro candidate mechanism for tumor necrosis induction in 
vivo should be dependent on TNFR80. In this study we de- 
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scribe the results of experiments with receptor-selective TNF  
mutants and antagonistic antibodies directed against the two 
TNF  receptors. These agents were analyzed for their ability to 
induce or inhibit the expression of tissue factor on endothelial 
cells in the presence of VEGF.  While a TNFR60-specific TNF  
mutant was superior to TNFR80-specific TNF  mutants for 
the induction of tissue factor, antagonistic antibodies to the 
TNFR80 were as effective as TNFR60 antagonistic antibodies 
in inhibiting tissue factor production by low concentrations of
TNF.  Therefore, a ligand passing mechanism is considered for 
the involvement of the TNFR80 in the TNF/VEGF synergy. 
2. Exper imental  procedures 
2.1. Materials 
Chemicals were purchased from Sigma (Munich, Germany) if not 
listed otherwise. Media and usual culture reagents were obtained from 
GIBCO (Eggenstein, Germany). The TNFR80-specific polyclonal rab- 
bit antiserum M80 and the production of antagonistic Fab fragments 
were produced as recently described [24]. Human umbilical cords were 
kindly donated from hospitals in the 'Wetterau'. Citrated pooled plas- 
ma was obtained from volunteers. 
2.2. Cell culture and assays 
Human umbilical vein endothelial cells (HUVEC) were prepared by 
the method of Jaffe [25] as modified by Thornton et al. [26]. HUVECs 
were cultured in MDCB131 medium supplemented with 10 mM 
HEPES (pH=7.4), 10% FCS (PAA, Linz, Austria), 100 lag/ml en- 
dothelial cell growth factor (ccpro, Neustadt, Germany), heparin (20 
Ixg/ml), 100 U/ml penicillin, 100 ~tg/ml streptomycin, 2 mM glutamine, 
2.5 Ixg/ml fungizone. Experiments were carried out within 48 h of the 
cells achieving confluence. Expression of tissue factor in endothelial 
cells was assessed by incubating cultures with TNF and/or purified 
recombinant VEGF in MDCB131 containing 10 mM HEPES 
(pH= 7.4), 10% FCS, 100 U/ml penicillin, 100 p.g/ml streptomycin, 
in the presence/absence of antibodies. For studies with neutralizing 
antibodies, cells were submitted to a 15 min incubation period before 
addition of the cytokines. Cells were incubated for 6 h at 37°C. Assays 
were carried out with whole cells obtained in suspension following 
scraping and tissue factor activity equivalents were determined as 
previously described [18]. 
2.3. Cytofluorometric analysis and binding studies with [a~S I]TNF 
HUVECs were washed and detached with 5 mM EDTA in HBSS/ 
25 mM HEPES. Incubation time with trypsin was not allowed to 
exceed 3min in total. Cells were incubated with primary unconjugated 
antibodies for 30 min at 4°C and 5 Ixg/ml as final concentration, 
washed twice with FACS buffer (PBS supplemented with 1% BSA 
and 0.1% NAN3) and then incubated with FITC-conjugated goat 
anti-mouse IgG for 30 min at 4°C. After washing twice, the cells 
were either analyzed immediately or fixed in 1% paraformaldehyde 
in PBS and stored at 4°C for later analysis. Flow cytometry analysis 
was performed on a FACStar (Becton Dickinson Immunocytochem- 
Table 1 
Binding competition of TNFR-specific antibodies with [leSI]TNF to 
HUVECs (P2) 
Addition Mean 25Jcpm %Competition 
± SD 
None 3987 ± 58 - 
Unlabeled TNF 1954± 50 100 
H398 2905 ± 73 53 
utr-1 3320± 97 33 
H398+utr-1 2046± 103 95 
HUVECs were preincubated with/without either anti-TNFR80 (utr- 
1), anti-TNFR60 (H398), both antibodies or an excess of unlabeled 
TNF before incubation with 20 ng/ml [125]TNF. 
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Fig. 1. Effect of a TNFR60-selective mutant on endothelial tissue 
factor production. Increasing concentrations of the TNFR60-selec- 
tive receptor mutant TNFR32W-S86T ([]) or wild-type TNF (A) 
were added, both in the presence of 2 nM VEGF. To demonstrate 
synergy, effects of the TNFR60-selective mutein in the absence of 
VEGF are also shown (©). Tissue factor was determined as de- 
scribed in the text. The mean of triplicates (+ S.D.) are shown. 
istry Systems, Mountain View, CA). TNF was labelled as described 
recently [6]. For competition binding studies cells were preincubated 
in triplicates with the specific TNFR antibodies H398 and utr-1 (30 
Ixg/ml each) for 90 min followed by an incubation period of 2 h with 
20 ng/ml 12SI-labeled TNF. Cells were washed twice and radioactivity 
was determined in a gamma-counter. All steps were carried out on ice. 
3. Results 
3.1. Synergistic induction of  tissue factor by VEGF and TNF  
receptor-selective TNF  mutants 
In the presence of VEGF already very low concentrations 
of TNF  can induce tissue factor expression on the surface of 
human umbilical cord vein cells (HUVEC). We analyzed more 
closely the involvement of the two distinct TNF  receptors in 
this system of TNF/VEGF synergy. Accordingly, all of the 
following experiments were performed in the presence of a 
constant optimal concentration of VEGF (2 nM), if not other- 
wise noted. In a first approach, we used mutants of the TNF  
molecule (muteins) which have previously been demonstrated 
to interact specifically with only one of the TNF  receptors and 
hence represent receptor-selective tools [2,3,8]. The TNFR60- 
selective TNF  mutant (TNFR32W-S86T) induced a dose-de- 
pendent production of tissue factor with a similar efficacy as 
wild-type TNF  (Fig. 1). Of note, only at lower concentrations 
the induction of tissue factor by TNFR32W-S86T was less 
efficient when compared to the effects induced by wild-type 
TNF.  Addition of the TNFR60-specific mutein in the absence 
of VEGF resulted in a much lower production of tissue factor, 
demonstrating that this mutein can efficiently synergize with 
VEGF (Fig. 1). In contrast, a TNFR80-specific mutein 
(TNFD143N-A145R) could not induce notable tissue factor 
production even at high concentrations up to 60 nM (Fig. 2). 
Bioactivity of the respective preparation of the TNF  mutein 
had been controlled in a thymocyte proliferation assay [27], 
showing an only 5-fold lower bioactivity compared to wild- 
type TNF  (data not shown). The highest TNFR80-specific 
mutein concentration used in this study exceeded the lowest 
active concentration tested in the thymocyte proliferation as- 
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Fig. 2. Effect of a TNFR80-selective mutant on endothelial tissue 
factor production. Increasing concentrations of TNFR80-selective 
receptor mutant TNFD143N-A145R ([]) were added together with 
2 nM VEGF, alone or in the presence of a low dose (10 pM) of the 
TNFR60-selective r ceptor mutant TNFR32W-S86T (zx). Tissue 
factor was measured as described in the text. The means of tripli- 
cates (_+ S.D.) are shown• 
say about 100-fold. Furthermore, we tested the possibility that 
TNFR80-dependent signalling can be only observed in the 
presence of a costimulation of TNFR60. However, no en- 
hancement of the cellular response was revealed by stimula- 
tion with the TNFR80-specific mutein in the presence of a 
suboptimal TNFR60 stimulation (Fig. 2). Similar results 
were obtained with a second TNFR80-specific mutein 
TNFD143F (data not shown). 
3,2. Analysis of TNF receptor expression 
The unresponsiveness of the HUVECs to the TNFR80-spe- 
cific mutein was not due to lack of TNFR80 expression since 
cells of the same passage (passage two) expressed both TNF 
receptors as demonstrated by FACS analysis (Fig. 3) and 
[125I]TNF binding composition studies (Table 1) using recep- 
tor-specific monoclonal antibodies. However, we observed 
that HUVECs tend to loose cell surface expression of 
TNFR80 upon prolonged cell culture (data not shown). 
Therefore, we used HUVECs of passage two throughout 
this study. 
3.3. Inhibition of VEGF-TNF synergy with neutralizing 
antibodies 
TNF receptor-specific neutralizing antibodies were investi- 
gated for their ability to influence the TNF-induced expres- 
sion of tissue factor in the presence of VEGF. For this pur- 
pose HUVECs were preincubated with either TNFR60- 
specific monoclonal ntibodies (H398) or with Fab fragments 
of TNFR80-specific purified polyclonal antibodies (M80). 
Blocking of TNF binding to TNFR60 completely abolished 
the TNF-mediated up-regulation of tissue factor at different 
TNF concentrations. This demonstrates that TNF binding to 
TNFR60 is essential for the synergy with VEGF at low (2 
pM) as well as at high (40 and 400 pM) TNF concentrations 
(Fig. 4). In contrast, a crucial involvement of TNFR80 in this 
response seems to be limited to low TNF concentrations. 
Blocking of TNF binding to TNFR80 strongly inhibited the 
TNF effect at low TNF concentration (2 pM) and (although 
less prominent) at a TNF concentration f 40 pM. However, 
VEGFFFNF synergy at a high TNF concentration (400 pM) 
was hardly TNFR80 dependent (Fig. 4). Similar results were 
obtained with a neutralizing monoclonal anti-TNFR80 anti- 
body (utr-1, data not shown). The decreased responsiveness of 
the TNFR80-specific antagonists at higher TNF concentra- 
tions was most probably not due to a lack in inhibition of 
TNF binding to TNFR80 because the same antibody effi- 
ciently blocked the TNF-induced, TNFR80-mediated prolif- 
eration of thymocytes [27] at TNF concentrations up to 1 nM 
(data not shown). 
4. Discussion 
In a previous tudy we have shown the principle capability 
of TNFR80 to induce tissue factor in HUVECs upon stimula- 
tion with membrane-bound TNF [27]. In the present study we 
focused on the interaction of the two TNF receptors with 
soluble TNF in the synergism of VEGF/TNF-induced tissue 
factor expression which has been implicated in TNF-induced 
tumor necrosis [18]. In particular, we were interested in the 
role of TNFR80 which was suggested to be involved in the 
process of tumor and scin necrosis [22,23]. The inability of 
TNFR80-selective TNF muteins to induce notable amounts of 
tissue factor in synergy with VEGF (in contrast o the effec- 
tive TNFR60-specific mutant), demonstrates that TNFR80 is 
not able to synergize with VEGF per se upon engagement 
with soluble TNF. These results are unlikely to be due to 
an unsufficient receptor expression since we could demon- 
strate TNFR80-expression on the surface of HUVECs with 
almost he same levels as observed with the TNFR60. More- 
over, a TNFR80-selective TNF mutein does not enhance 
TNFR60-induced responses. This argues against direct signal- 
ling of TNFRS0, at least with respect o tissue factor induc- 
tion. 
As an additional possibility for cooperation of TNFR80 
with TNFR60 we considered a ligand passing function of 
the TNFR80, first suggested by Tartaglia et al. [14]. In this 
model, the TNFR80, due to its higher on- and off-rates, 
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Fig. 3. Cytofluorometric determination of TNFR expression on HU- 
VECs of passage two. Cells were incubated with mAb H398, specific 
for TNFR60 and with utr-1, specific for TNFR80. Further proce- 
dure and the measurements were performed as described in the text. 
Isotype-matched control antibodies (Co-IgG) were used to deter- 
mine the background staining. 
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Fig. 4. Effect of neutralizing antibodies specific for either one of the 
TNF receptors. HUVECs were pretreated with either anti-TNFR80 
(20 ~tg/ml) or anti-TNFR60 (10 lag/ml) antibodies. Different TNF 
concentrations a indicated were added together with 1 nM VEGF 
(TNF + VEGF). To demonstrate synergy, effects of VEGF (1 nM) 
or TNF (concentration as indicated) alone are also shown. Tissue 
factor was measured as described in the text. The means of tripli- 
cates (+ S.D.) are shown. 
passes the ligand to the signalling molecule TNFR60 posses- 
sing lower on- and off-rates. This mechanism should be im- 
portant at low concentrations of TNF when TNFR60 signal- 
ling is limited by low ligand interaction due to the slow 
kinetics. In contrast, at higher concentrations of TNF, the 
supportive function of TNFR80 becomes less important be- 
cause direct ligand binding to TNFR60 can take place. In- 
deed, our studies with antagonistic antibodies demonstrate 
that TNFR80 appears to be supportive for the TNF/VEGF 
synergism only at low concentrations of TNF, whereas TNF 
binding to TNFR60 is essential at all concentrations being 
tested. In a recent report, tissue factor production in HU- 
VECs by TNF in the absence of VEGF was shown to be 
considerably less dependent on TNFR80 [5] as found here. 
These findings can be easily explained by the fact that in 
the presence of VEGF the minimum effective concentration 
of TNF is so dramatically lowered that TNFR60-mediated 
signalling is completely dependent on ligand passing by the 
TNFR80. 
Because our findings uggest that TNFR80 enhances tissue 
factor production independent of intracellular signalling, it is 
most likely that some type of interaction between both recep- 
tors occurs. Besides the mechanism of ligand passing, it can- 
not be ruled out completely that the TNFR80 contributes to 
the observed synergy by forming receptor heteromers with the 
TNFR60. Studies using TNF receptor muteins can not ad- 
dress the question of heterodimerization, which should be 
observed with wild-type TNF only. However, in a previous 
study, using a different approach, heterodimerization of the 
two types of TNF receptor had not been observed [24]. In 
conclusion, this study suggests that low-dose TNF-mediated 
tissue factor induction on the endothelium of tumors produc- 
ing significant amounts of VEGF is dependent on the 
TNFR80 and thus a possible candidate mechanism for the 
induction of necrosis [22,23]. The final evaluation of this as- 
pect, however, is difficult because no data exist regarding the 
actual TNF concentration inside the tumor vasulature neces- 
sary to induce tumor necrosis. 
The possible involvement in tumor necrosis induction may 
not be the only biological function of tissue factor production 
caused by the synergistic TNF/VEGF interaction. Expression 
of tissue factor in the endothelium of tumor vessels and within 
the tumor cells seems to correlate with the switch to the ma- 
lignant and angiogenic phenotype of breast carcinomas [28]. 
In addition, tissue factor 'knockouts' in mice revealed an im- 
paired pattern of extra-embryonic blood vessel formation dur- 
ing early embryogenesis (Peter Carmeliet, personal communi- 
cation). In light of the fact that both TNF and VEGF can 
induce angiogenesis in vivo [29,30], a possible involvement of
the here described synergistic tissue factor induction in angio- 
genic processes may be considered, especially when low con- 
centrations of TNF and high concentrations of VEGF are 
present. Candidate pathological situations, when VEGF and 
its receptors are up-regulated, had been described for tumors 
[31,32], rheumatoid arthritis [33,34] and hypoxic lungs [35], 
but coexpression of TNF has not been studied in all of these 
examples. Further experimental in vivo data are required to 
test the hypothesis that TNF/VEGF-mediated tissue factor 
production is also involved in angiogenesis. 
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